Inclusion Criteria:
* Voluntary participation and signed informed consent before any study procedures, with full understanding of the study content, procedures, and potential adverse reactions.
* Healthy Chinese adult males or females aged 18 to 55 years (inclusive).
* Body weight ≥50 kg for males and ≥45 kg for females, and body mass index (BMI) between 18 and 28 kg/m² (inclusive).
* Judged by the investigator to be in good health, with medical history, laboratory tests, physical examination, vital signs, and ECG results being normal or abnormal without clinical significance.
* Participants and their partners must have no pregnancy plan and agree to use effective non-drug contraceptive measures (e.g., condoms, non-medicated intrauterine devices) from 2 weeks before screening until 6 months after the end of the study, unless permanent sterilization has been performed (e.g., bilateral tubal ligation, vasectomy).
* Willing to comply with the visit schedule, study treatment, laboratory tests, and other study-related procedures and requirements as specified in the protocol.
Exclusion Criteria:
* Average daily smoking \>5 cigarettes within 3 months before dosing.
* History of headaches (e.g., migraine, tension-type headache).
* Allergic constitution (multiple drug or food allergies) or intolerance/allergy to the active ingredient or excipients of the study drugs.
* History of alcohol abuse (≥14 units of alcohol per week; 1 unit = 285 mL beer, 25 mL spirits, or 100 mL wine).
* History of drug abuse or use of illicit drugs within 5 years before dosing.
* Blood donation or significant blood loss (≥400 mL) within 3 months before dosing, or planned blood donation during the study.
* Any disease that increases bleeding risk, such as acute gastritis or gastric/duodenal ulcer.
* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or genetic conditions predisposing to MTC.
* History of pancreatitis or symptomatic gallbladder disease.
* Serum calcitonin \> upper limit of normal (ULN) at screening.
* Dysphagia, or gastrointestinal disorders affecting absorption (e.g., diarrhea, vomiting, inflammatory bowel disease, active ulcer), or history of gastrointestinal surgery leading to malabsorption, or long-term use of drugs affecting gastrointestinal motility (e.g., bariatric surgery such as gastric banding).
* Special dietary requirements and unable to accept standardized meals.
* Surgery within 3 months before dosing, or planned surgery during the study, or surgery that affects drug absorption, distribution, metabolism, or excretion.
* Received live attenuated vaccine within 1 month before dosing, or planned vaccination during the study.
* Use of any prescription drug, over-the-counter drug, vitamin product, or herbal medicine within 14 days before dosing.
* Significant changes in diet or exercise habits within 3 months before dosing.
* Use of CYP3A4 inhibitors, CYP3A4 inducers, or P-gp inhibitors within 14 days before the first dose, or planned use during the study.
* Participation in another clinical trial or receipt of an investigational drug within 3 months before dosing (unless the participant withdrew before treatment/randomization).
* ECG abnormalities with clinical significance at screening; QTcF \>450 msec (males) or \>470 msec (females) by Fridericia's correction.
* Pregnant, lactating, or positive pregnancy test in females of childbearing potential.
* Clinically significant laboratory abnormalities, or clinically significant diseases within 12 months before dosing (respiratory, circulatory, digestive, endocrine, rheumatic/immune, nervous, hematologic, or psychiatric disorders) that make the participant unsuitable for the study.
* Positive screening for hepatitis B surface antigen, hepatitis C antibody/core antigen, HIV antibody, or syphilis antibody.
* Acute illness or concomitant medication between screening and first dose.
* Positive alcohol breath test or urine drug screen.
* Any other condition judged by the investigator as unsuitable for participation.
